Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.

Rhizoxin is a new anti-tumour agent isolated from the pathogenic fungus Rhizopus chinensis. It has shown broad activity against murine tumour models and is also active against vinca alkaloid-resistant cells. The purpose of our studies was to determine the clinical activity of this compound in patien...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Hanauske, A. R., Catimel, G., Aamdal, S., ten Bokkel Huinink, W., Paridaens, R., Pavlidis, N., Kaye, S. B., te Velde, A., Wanders, J., Verweij, J.
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 1996
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2074418/
https://ncbi.nlm.nih.gov/pubmed/8562349
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares